The SFDA CEO Meets with Pharmaceutical Companies to Strengthen Investor Support

H.E. Dr. Hisham S. Aljadhey, CEO of the Saudi Food and Drug Authority (SFDA), met at the Authority’s headquarters in Riyadh with several chief executives and representatives of local and international pharmaceutical companies to discuss key issues and opportunities that will contribute to the growth and support of the pharmaceutical sector in the Kingdom.

The meeting is part of the SFDA’s ongoing efforts to enhance its partnership with the private sector and foster direct channels of communication with representatives. It provided a platform to address current challenges, explore future opportunities, and exchange perspectives on how to further strengthen investment, innovation, and competitiveness in the Saudi pharmaceutical market.

Discussions also focused on regulatory strategies and enablers that support a sustainable and attractive investment environment, in alignment with the goals of Saudi Vision 2030. This effects aimed at reinforcing the Kingdom’s position as a leading regional and global hub for pharmaceutical industries.

Participants also reviewed the challenges facing the private sector and proposed practical and innovative solutions to overcome them, aiming to ensure continued progress and sustainable growth within this vital industry.

This meeting reflects the SFDA’s commitment to transparency and active engagement with its partners, fostering an enabling environment for collaboration between the public and private sectors. It further contributes to achieving the goals of the Health Sector Transformation Program, one of Vision 2030’s key initiatives, and supports the SFDA’s mission to protect public health and ensure the availability of safe, effective, and high-quality medicines for society.